The use of antibody engineering to create novel drugs that target N-methyl-D-aspartate receptors

Joseph R. Moskal*, Hirotaka Yamamoto, Patricia A. Colley

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

15 Scopus citations

Abstract

According to a recent World Health Organization survey, there are over four hundred million people worldwide suffering from mental and neurological disorders; schizophrenia affects some forty-five million people, and unipolar major depression ranked fifth in major causes of disability and death. Clearly it is of the utmost importance to develop new, effective, and safe neuro-pharmaceuticals with this increasing "global burden of disease". To this end, we have developed a strategy of generating monoclonal antibodies that act as modulators of the cell-surface central nervous system receptor-ion channel complexes. In this review we will focus on the generation and characterization of a monoclonal antibody that acts as a partial agonist to the N-methyl-D-aspartate receptor. The creation of peptide mimetics, derived from this monoclonal antibody, that may be useful as cognitive enhancers and protect neurons hypoxic and ischemic insults caused by stroke, will also be discussed.

Original languageEnglish (US)
Pages (from-to)331-345
Number of pages15
JournalCurrent Drug Targets
Volume2
Issue number3
DOIs
StatePublished - 2001

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Fingerprint Dive into the research topics of 'The use of antibody engineering to create novel drugs that target N-methyl-D-aspartate receptors'. Together they form a unique fingerprint.

Cite this